iShares Biotechnology ETF
897 hedge funds and large institutions have $5.41B invested in iShares Biotechnology ETF in 2022 Q1 according to their latest regulatory filings, with 82 funds opening new positions, 259 increasing their positions, 330 reducing their positions, and 135 closing their positions.
30% more funds holding in top 10
Funds holding in top 10: 10 → 13 (+3)
12% more call options, than puts
Call options by funds: $285M | Put options by funds: $254M
2.09% less ownership
Funds ownership: 63.31% → 61.21% (-2.1%)
7% less funds holding
Funds holding: 963 → 897 (-66)
15% less capital invested
Capital invested by funds: $6.38B → $5.41B (-$976M)
22% less repeat investments, than reductions
Existing positions increased: 259 | Existing positions reduced: 330
39% less first-time investments, than exits
New positions opened: 82 | Existing positions closed: 135
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$86.3M |
| 2 |
Jane Street
New York
|
+$63.7M |
| 3 |
Goldman Sachs
New York
|
+$51.5M |
| 4 |
Bessemer Group
Woodbridge,
New Jersey
|
+$51.4M |
| 5 |
Citigroup
New York
|
+$49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$107M |
| 2 |
Morgan Stanley
New York
|
-$94.3M |
| 3 |
CI Investments Inc
Toronto,
Ontario, Canada
|
-$73.8M |
| 4 |
Two Sigma Advisers
New York
|
-$38M |
| 5 |
Two Sigma Investments
New York
|
-$34.8M |
IBB Hedge Fund Activity: Q1 2022 in Review
897 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q1 2022, worth a combined $5.41B — down 15% from $6.38B a quarter earlier.
Sellers outnumbered buyers: 135 funds closed out of IBB and 82 opened new positions — a net loss of 53 holders — while 330 trimmed existing stakes and 259 added.
The largest buyer was Bank of America, adding an estimated $86.3M. The largest seller was Healthcare of Ontario Pension Plan (HOOPP) Trust Fund, cutting an estimated $107M.
- 897 institutional investors held iShares Biotechnology ETF (IBB) as of Q1 2022, down from 963 in Q4 2021.
- Funds reported $5.41B of iShares Biotechnology ETF stock for Q1 2022, down 15% quarter-over-quarter.
- 82 funds opened new iShares Biotechnology ETF positions in Q1 2022 and 135 closed out, a net change of -53 holders.
- The largest iShares Biotechnology ETF buyer in Q1 2022 was Bank of America, an estimated $86.3M added.
- The largest iShares Biotechnology ETF seller in Q1 2022 was Healthcare of Ontario Pension Plan (HOOPP) Trust Fund, an estimated $107M sold.
Based on aggregated 13F filings for Q1 2022.